Back to results
US 2026/0217830 A1Published application
Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
AssigneeAmgen Inc.
InventorsXin YU, Wenjun OUYANG, Chi-Ming Kevin LI, Jackson Graeme EGEN, Oh Kyu YOON, Ian Halsey DRIVER, Shunsuke TAKENAKA, Christy Ann THOMSON, Hongyu WANG
Life of this patent
Estimating the term…
Abstract
This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.
Claims12
An antibody, or antigen-binding fragment thereof, that binds LILRB1 and comprises:
- (i) a heavy chain variable region (VH) that comprises:
- (a) a VH CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 36, 48, or 58;
- (b) a VH CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 37, 49, or 59;
- and
- (c) a VH CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 38, 50, or 60;
- and
- (ii) a light chain variable region (VL) that comprises:
- (a) a VL CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 39, 51, or 61;
- (b) a VL CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 40, 52, or 62;
- and
- (c) a VL CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 41, 53, or 63.
14 more elements
Dependencies are inferred from the claim text.